Ex-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration

dc.contributor.authorFernández Campos, Francisco
dc.contributor.authorClares Naveros, Beatriz
dc.contributor.authorRodríguez Lagunas, María José
dc.contributor.authorJáuregui Pallarés, Olga
dc.contributor.authorCasals i Ribes, Isidre
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.date.accessioned2020-02-24T11:56:04Z
dc.date.available2020-02-24T11:56:04Z
dc.date.issued2019-08-21
dc.date.updated2020-02-24T11:56:04Z
dc.description.abstractRhinosinusitis is a prevalent disorder with a severe impact on the health-related quality of life. Saponins of Cyclamen europaeum exert a clinically proven curative effect on rhinosinusitis symptoms when instilled into the nasal cavity, however, more extensive preclinical assessment is required to better characterize the efficacy of this botanical extract. This work evaluates the potential use of a natural freeze-dried extract of C. europaeum given as topical nasal administration. Permeation experiment on porcine nasal mucosa was performed with Franz diffusion cells. Experiments in rabbits were performed to test for any toxicological, hematological, biochemical or histological evidence of systemic action. No theoretical levels of saponins were found in the receptor chamber of Franz diffusion cells. Hematological data did not show significant differences between control and experimental animals (p > 0.05). Histological studies also showed that enhanced secretory activity in response to intranasal administration was not accompanied by any visible signs of injury. An examination of the brain, lungs, liver, kidneys, spleen, and gastrointestinal organs did not reveal any abnormality. The absence of mucosal permeation of saponins and negligible probability of C. europaeum saponins absorption in the course of a therapeutic application was demonstrated.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691106
dc.identifier.issn1999-4923
dc.identifier.pmid31438642
dc.identifier.urihttps://hdl.handle.net/2445/151059
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11090426
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 9, p. 426
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11090426
dc.rightscc-by (c) Fernández Campos, Francisco et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationFormes farmacèutiques
dc.subject.classificationMalalties del nas
dc.subject.classificationDrogues
dc.subject.otherPharmaceutical dosage forms
dc.subject.otherNose diseases
dc.subject.otherDrugs of abuse
dc.titleEx-Vivo and In-Vivo Assessment of Cyclamen europaeum Extract After Nasal Administration
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
691106.pdf
Mida:
2.26 MB
Format:
Adobe Portable Document Format